ABVC BioPharma Inc (ABVC)
1.42
-0.17
(-10.69%)
USD |
NASDAQ |
Apr 26, 16:00
1.44
+0.02
(+1.41%)
After-Hours: 20:00
ABVC BioPharma Enterprise Value: 16.07M for April 26, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 26, 2024 | 16.07M |
| April 25, 2024 | 17.86M |
| April 24, 2024 | 16.70M |
| April 23, 2024 | 15.33M |
| April 22, 2024 | 12.06M |
| April 19, 2024 | 11.53M |
| April 18, 2024 | 12.16M |
| April 17, 2024 | 11.84M |
| April 16, 2024 | 12.90M |
| April 15, 2024 | 12.58M |
| April 12, 2024 | 12.58M |
| April 11, 2024 | 13.22M |
| April 10, 2024 | 13.11M |
| April 09, 2024 | 13.53M |
| April 08, 2024 | 14.27M |
| April 05, 2024 | 14.48M |
| April 04, 2024 | 14.59M |
| April 03, 2024 | 14.70M |
| April 02, 2024 | 14.70M |
| April 01, 2024 | 15.54M |
| March 28, 2024 | 14.91M |
| March 27, 2024 | 13.74M |
| March 26, 2024 | 14.59M |
| March 25, 2024 | 12.16M |
| March 22, 2024 | 12.37M |
| Date | Value |
|---|---|
| March 21, 2024 | 12.27M |
| March 20, 2024 | 12.38M |
| March 19, 2024 | 12.90M |
| March 18, 2024 | 13.32M |
| March 15, 2024 | 13.43M |
| March 14, 2024 | 13.74M |
| March 13, 2024 | 14.06M |
| March 12, 2024 | 14.38M |
| March 11, 2024 | 13.96M |
| March 08, 2024 | 14.27M |
| March 07, 2024 | 11.76M |
| March 06, 2024 | 11.68M |
| March 05, 2024 | 11.42M |
| March 04, 2024 | 11.68M |
| March 01, 2024 | 11.17M |
| February 29, 2024 | 11.42M |
| February 28, 2024 | 11.47M |
| February 27, 2024 | 11.59M |
| February 26, 2024 | 11.68M |
| February 23, 2024 | 11.34M |
| February 22, 2024 | 11.42M |
| February 21, 2024 | 11.25M |
| February 20, 2024 | 11.34M |
| February 16, 2024 | 11.94M |
| February 15, 2024 | 12.02M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
5.806M
Minimum
Oct 06 2023
400.60M
Maximum
Apr 29 2019
73.18M
Average
64.33M
Median
Jun 01 2022
Enterprise Value Benchmarks
| NeuBase Therapeutics Inc | -10.93M |
| Sutro Biopharma Inc | -108.49M |
| Reviva Pharmaceuticals Holdings Inc | 60.11M |
| Flora Growth Corp | 12.11M |
| Journey Medical Corp | 54.95M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.111M |
| Revenue (Quarterly) | 0.0022M |
| Total Expenses (Quarterly) | 1.964M |
| EPS Diluted (Quarterly) | -0.3931 |
| Gross Profit Margin (Quarterly) | -6.33K% |
| Profit Margin (Quarterly) | -143.7K% |
| Earnings Yield | -175.6% |
| Normalized Earnings Yield | -173.56 |